NCT06673056

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T: A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: IntraBio Inc · Industry
• Sex: All
• Age: 4 Years
• Healthy volunteers: Not accepted

Summary

A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Detailed description

This is a multinational, randomized, placebo-controlled, double-blinded, cross-over Phase III study that will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) versus Placebo for the treatment of Ataxia-Telangiectasia (A-T). Patients will be assessed during three study periods: a baseline period (approximately 2-weeks), after which they will be randomized (1:1) to receive treatment with IB1001 or Placebo for approximately 12-weeks during the first intervention period ("Period I"). Following Period I, patients will crossover to receive the opposite treatment (IB1001 or Placebo) for approximately 12-weeks during a second intervention period ("Period II). Patients will be assessed twice during each study period. Patients who have participated in the study may be offered the opportunity to roll over into an Extension Phase, which is planned to allow patients to have further access to IB1001.

Conditions

• Ataxia-Telangiectasia
• Ataxia-Telangiectasia (A-T)

Interventions

Type	Name	Description
DRUG	N-Acetyl-L-Leucine	N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
OTHER	Placebo	Matching Placebo Sachet

Timeline

• Start date: 2025-03-18
• Primary completion: 2027-12-31
• Completion: 2028-06-01
• First posted: 2024-11-04
• Last updated: 2025-07-03

Locations

11 sites across 6 countries: United States, Germany, Slovakia, Spain, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study